Patients with this subtype of ovarian cancer who are negative for somatic mutations of the BRCA1 and BRCA2 genes will be subsequently tested for HRD (Homologous Recombination Deficiency) score evaluation. Here, BRCA2 is linked to ovarian carcinoma.